Christine Brezden-Masley, MD PhD FRCPC

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Astellas
    Topic:
    Clinical trial and Advisory Board
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    08/01/2027
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Astra Zeneca
    Topic:
    Clinical trial; Research grant; Advisory Board; Speaker fees
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    02/28/2028
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    BMS
    Topic:
    Research; Speaker fees; Advisory board
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    02/28/2028
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Beigene
    Topic:
    Advisory board
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    02/23/2026
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Daiichi-Sankyo
    Topic:
    Advisory board; Speaker fees; Clinical trial
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    02/28/2027
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Knight
    Topic:
    Advisory board; Speaker fees
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    02/28/2027
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Gilead Sciences
    Topic:
    Clinical trial, Speaker fees, Advisory board
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    02/28/2027
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Eli Lilly
    Topic:
    Advisory board, Speaker fees, Research Grant
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    02/28/2027
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Merck
    Topic:
    Advisory board, Clinical trial, Speaker fees
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    02/28/2027
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Novartis
    Topic:
    Clinical trial, Research Grant, Speaker fees
    Date added:
    02/24/2025
    Date updated:
    02/24/2025
    Relationship end date:
    02/28/2027

Pages

Return to 103 Cardiology Grand Rounds (022625)

 

**Disclaimer**

This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.